In addition, a comparison of Orai1:Orai3 gene expression ratios and electrophysiological profiles upon application of 2-APB in prostate cancer cell lines LNCaP, DU145 and hPEC support the idea of low levels of Orai3 in prostate cancer, although Orai3 is not reduced per se in cancer. This evidence concerns the gene ORAI1 and prostate cancer.